Invention Grant
- Patent Title: Reduction of the incidence or recurrence of breast cancer in postmenopausal women treated with intravaginal sex steroid precursor
-
Application No.: US17538875Application Date: 2021-11-30
-
Publication No.: US11690852B2Publication Date: 2023-07-04
- Inventor: Fernand Labrie , Erick Moyneur , Alain Dury , Sylvain Gauthier
- Applicant: Endorecherche, Inc.
- Applicant Address: CA Québec
- Assignee: Endorecherche, Inc.
- Current Assignee: Endorecherche, Inc.
- Current Assignee Address: CA Québec
- Agency: Ostrolenk Faber LLP
- Main IPC: A61K31/566
- IPC: A61K31/566 ; A61K31/453 ; A61K9/00 ; A61P35/00 ; A61P15/00
Abstract:
The present invention relates to the intravaginal use of sex steroid precursor (e.g. DHEA) for the reduction of the incidence or recurrence of breast cancer in postmenopausal women. The dosage of sex steroid precursor is limited to 25 mg per day or less. Further administration of selective estrogen receptor modulator is disclosed for the above-reduction.
Public/Granted literature
Information query
